Dopamine agonists for hyperprolactinaemia

[1]  M. Molitch.  Pituitary tumors: Cabergoline versus bromocriptine: a meta-analysis? , 2011, Nature Reviews Endocrinology.

[2]  W. A. Mann.  Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach , 2011, European journal of clinical investigation.

[3]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[4]  R. El Dib,et al.  Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis , 2011, Pituitary.

[5]  G. Creatsas,et al.  Evaluation and management of adolescent amenorrhea , 2010, Annals of the New York Academy of Sciences.

[6]  Yan Wang,et al.  Effectiveness of bromocriptine monotherapy or combination treatment with clomiphene for infertility in women with galactorrhea and normal prolactin: A systematic review and meta-analysis. , 2010, Current therapeutic research, clinical and experimental.

[7]  O. Dekkers,et al.  Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  C. E. Cervantes,et al.  [Cabergoline in hyperprolactinemia and valvular heart disease]. , 2009, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

[9]  P. Souverein,et al.  Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  T. Vos,et al.  Cost-Effectiveness of Interventions to Promote Physical Activity: A Modelling Study , 2009, PLoS medicine.

[11]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[12]  N. Martin,et al.  Dopamine agonists and hyperprolactinaemia , 2009, BMJ : British Medical Journal.

[13]  C. Cervantes,et al.  Cabergolina en la hiperprolactinemia y enfermedad valvular cardíaca , 2009 .

[14]  Elena S. Di Martino,et al.  Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies , 2008, Journal of endocrinological investigation.

[15]  Jonathan A C Sterne,et al.  Investigating and Dealing with Publication and Other Biases , 2008 .

[16]  B. Delemer,et al.  Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology. , 2007, Annales d'endocrinologie.

[17]  I. Olkin,et al.  The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.

[18]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[19]  M. Molitch.  Pituitary disorders during pregnancy. , 2006, Endocrinology and metabolism clinics of North America.

[20]  A. Barlier,et al.  Quinagolide--a valuable treatment option for hyperprolactinaemia. , 2006, European journal of endocrinology.

[21]  J. Jackson,et al.  Clinical inquiries. What is the recommended evaluation and treatment for elevated serum prolactin? , 2005, The Journal of family practice.

[22]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[23]  H. Zacur,et al.  Dopamine Agonist Therapy for Hyperprolactinemia , 2003, Clinical obstetrics and gynecology.

[24]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[25]  A. Colao,et al.  Dopamine receptor agonists for treating prolactinomas , 2002, Expert opinion on investigational drugs.

[26]  P. Marzullo,et al.  The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas , 2000, Clinical endocrinology.

[27]  A. Khandji,et al.  Long-term treatment of prolactin-secreting macroadenomas with pergolide. , 2000, The Journal of clinical endocrinology and metabolism.

[28]  A. Luciano,et al.  Clinical presentation of hyperprolactinemia. , 1999, The Journal of reproductive medicine.

[29]  B. Biller.  Diagnostic evaluation of hyperprolactinemia. , 1999, The Journal of reproductive medicine.

[30]  M. Molitch,et al.  Guidelines for the diagnosis and treatment of hyperprolactinemia. , 1999, The Journal of reproductive medicine.

[31]  P. Conner,et al.  Hyperprolactinemia; etiology, diagnosis and treatment alternatives , 1998, Acta obstetricia et gynecologica Scandinavica.

[32]  J. Webster.  A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation , 1996 .

[33]  T. Mindermann,et al.  Age‐related and gender‐related occurrence of pituitary adenomas , 1994, Clinical endocrinology.

[34]  F. Flamigni,et al.  Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study , 1992, Clinical endocrinology.

[35]  L. Wide,et al.  LONG‐TERM TREATMENT WITH A NEW NON‐ERGOT LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, IN WOMEN WITH HYPERPROLACTINAEMIA , 1988, Clinical endocrinology.

[36]  A. Klibanski,et al.  Decreased bone density in hyperprolactinemic women. , 1980, The New England journal of medicine.